Upcoming events

GPIIbIII inhibitors : still useful in 2013?

Chairpersons: D. Angiolillo, D. Dudek

Presentations available when logged in:

  • The effect of glycoprotein IIb/IIIa inhibitors on mortality following PCI for NSTE-ACS
  • Intracoronary bivalirudin alone versus abciximab plus heparin regimen in primary PCI
  • High bolus dose tirofiban compared with abciximab in primary PCI: a propensity score matched outcome study
  • Similar anti-inflammatory effects of intracoronary and intravenous abciximab administration during primary PCI: a single centre open label randomis...
  • Eptifibatide and abciximab are associated with similar outcomes when used during primary PCI for STEMI